High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents

Leandro Soriano-Guillén¹,2, Bárbara Hernández-García¹, Jimena Pita², Nieves Domínguez-Garrido¹, Genoveva Del Río-Camacho¹ and Adela Rovira²,³

¹Department of Pediatrics, Fundación Jimenez Diaz, University Autonoma of Madrid, Avenida Reyes Catolicos no 2, 28040 Madrid, Spain, ²Laboratory of Endocrinology and ³Department of Endocrinology, Fundacion Jimenez Diaz, University Autonoma of Madrid, Madrid, Spain

(Author correspondence should be addressed to L. Soriano-Guillén; Email: lgsoriano@fjd.es; leensor4@hotmail.com)

Abstract

Objective: We intend to assess the utility of the high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular risk in obese children and adolescents.

Methods: The study included children and adolescents between 6 and 18 years of age with a body mass index (BMI) higher than 2 SDS. All the patients had their blood pressure taken and hs-CRP, hepatic function, lipid profile and uric acid were determined after 12 h of fasting. Likewise, an oral glucose tolerance test was performed, determining basal glucose and insulin levels, and after stimulus. We considered the presence of metabolic syndrome when the obese children and teenagers showed at least two of the following conditions: decreased high density lipoprotein (HDL)-cholesterol, hypertriglyceridemia, hypertension or alteration in glucose metabolism.

Results: Out of the 115 obese children studied, 24% showed signs of metabolic syndrome. Those with metabolic syndrome presented higher levels of hs-CRP (mean: 3.8 mg/l; 95% CI: 2.8–4.8) in comparison with the obese patients who did not show signs of metabolic syndrome (mean: 2 mg/l; 95% CI: 1.5–2.5). After a multivariate analysis, the variables that appear to influence the changes in hs-CRP were BMI, triglycerides and HDL-cholesterol levels.

Conclusion: The hs-CRP is a useful tool for early diagnosis of cardiovascular risk in obese children and teenagers.

Introduction

The rise in C-reactive protein (CRP) as a response to the increase in the secretion of cytokines of adipose origin detected in obese individuals (1) has been used as a marker of cardiovascular risk and diabetes in adults (2, 3). When measured with new high-sensitivity assays, the levels of CRP have proven to predict future cardiovascular risk. Among apparently healthy men and women, the levels of high-sensitivity-CRP (hs-CRP) of < 1, 1–3 and > 3 mg/l distinguish between those at low, moderate and high risk of future cardiovascular disease (4).

Later studies have shown high values of hs-CRP among obese children and adolescents, indicating that in early stages there already exists a certain level of inflammation in relation to the non-obese population (5–8). However, not many data are available that guarantee its utility as a marker of cardiovascular risk and diabetes in childhood (7, 8). Therefore, our intention is to study the levels of hs-CRP in obese children and adolescents with and without metabolic syndrome to evaluate the utility of this parameter as a method of early diagnosis of cardiovascular risk in early stages of life and to analyse whether there are variables associated with higher levels of CRP.

Subjects and methods

This is a cross-sectional study of obese children and adolescents. From all children and adolescents between 6 and 18 years of age, who came to our Unit (Pediatric Endocrinology Unit of Hospital Fundacion Jimenez Diaz, Madrid) and who were suspiciously obese, we recruited those who had body mass index (BMI) > 2 SDS for their age and sex according to Spanish BMI data and who did not suffer any chronic illness or acute infectious disease.

Considering that the average level of hs-CRP in the normal population is around 1 mg/l, to achieve a 50% difference in hs-CRP levels among obese individuals with and without metabolic syndrome, it is necessary to obtain a minimum sample size of 90 patients with a statistical power of 90% and a confidence level of 95%.

These children and adolescents had their weight (kg), height (cm) and blood pressure (mmHg) taken thrice during a period of time of 10 min (we calculated the mean...
systolic and diastolic blood pressure). After 12 h of night fasting, blood samples were taken to measure hs-CRP, lipid profile, hepatic function, basal glucose and insulin levels. Later, a glucose tolerance test was carried out (1.7 g/kg, maximum = 75 g) and then, 120 min later, glucose and insulin levels were measured again. Taking into account that all our patients met one criterion of metabolic syndrome (being obese), metabolic syndrome was considered when at least two other of the following criteria were present (9, 10): HDL cholesterol below 5 percentile and/or triglycerides above 95 percentile for the age and sex, diastolic and/or systolic blood pressure higher than 95 percentile for the age, sex and height (11), and alteration in glucose metabolism according to criteria of the American Society of Diabetes (12). Other study variables taken into account include age, sex, race and Tanner stages of pubertal development.

This project was approved by the Ethics Committee of our hospital and it was compulsory to sign the corresponding informed consent in order to take part.

Student’s t-test was used to compare independent data of normal distribution, applying the Mann–Whitney U test when the variables did not follow a normal distribution. Finally, in order to analyse the correlation between the levels of hs-CRP and the study variables, a univariate analysis was carried out and later a multivariate linear regression was performed. The data were analysed using the SAS software package (SAS Institute Inc., Cary, NC, USA).

Results

The data have been expressed as mean and in 95% confidence interval. A total of 115 obese children and adolescents were studied, of whom 28 met metabolic syndrome criteria (24%). The children and adolescents with metabolic syndrome presented significantly higher levels of hs-CRP (mean: 3.8 mg/l; 95% CI: 2.8–4.8) in comparison with those who did not present metabolic syndrome (mean: 2 mg/l; 95% CI: 1.5–2.5) (Table 1). There were also significant differences between these two groups when analysing the levels of basal insulin and 120 min later, triglycerides, HDL-cholesterol and uric acid. By contrast, no significant differences between the two groups were observed regarding age and BMI. Finally, there were no differences in the levels of hs-CRP when comparing the different pubertal stages, race and sex.

After performing a simple linear regression between the different quantitative variables that could affect the hs-CRP, the only ones that showed a linear relationship were BMI (r = 0.35, P < 0.01), basal insulin (r = 0.3, P = 0.01), triglycerides (r = 0.33, P < 0.01) and HDL-cholesterol (r = −0.3, P < 0.01) (Fig. 1), although with a remarkable dispersion. Later on, a multivariate linear regression model was built considering hs-CRP as a dependent variable and BMI, basal insulin, triglycerides and HDL-cholesterol as independent variables. In this model, the only significant variables were BMI, triglycerides and HDL-cholesterol, with a determination coefficient of R² = 0.25.

Conclusion

The hs-CRP is significantly increased in obese children and adolescents with metabolic syndrome in comparison with the group without metabolic syndrome. With this study, we have shown that BMI is not the only variable that can affect the increase in hs-CRP, unlike what has been described in previous studies (5, 6). Therefore, a possible interaction is found between hs-CRP and the levels of triglycerides and HDL-cholesterol, suggesting its utility as a metabolic risk marker (7, 8). This interaction between hs-CRP, triglycerides and HDL-cholesterol could be mediated by different cytokines of adipose origin that

---

**Table 1** Comparison of clinical and biochemical data among obese children with or without metabolic syndrome.

<table>
<thead>
<tr>
<th></th>
<th>Metabolic syndrome (n=28)</th>
<th>Without metabolic syndrome (n=87)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hs-CRP (mg/l)</td>
<td>3.8 (2.8–4.8)</td>
<td>2 (1.5–2.5)</td>
<td>&lt;0.01&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Age (years)</td>
<td>11.4 (10.4–12.4)</td>
<td>10.6 (9.7–11.3)</td>
<td>0.25&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>BMI (SDS)</td>
<td>4.7 (4–5.4)</td>
<td>4 (3.6–4.4)</td>
<td>0.06&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>ALAT (UI/l)</td>
<td>30 (21–39)</td>
<td>28 (23–33)</td>
<td>0.61&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>ASAT (UI/l)</td>
<td>42 (22–62)</td>
<td>27 (19–36)</td>
<td>0.13&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>4.47 (4.30–4.64)</td>
<td>4.42 (4.29–4.55)</td>
<td>0.64&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Basal insulin (μU/ml)</td>
<td>32.1 (25.2–38.9)</td>
<td>16.3 (14.2–18.4)</td>
<td>&lt;0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HOMA-index</td>
<td>6.37 (4.90–7.84)</td>
<td>3.22 (2.75–3.69)</td>
<td>&lt;0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Glucose 120 (mmol/l)</td>
<td>6.88 (6.30–7.46)</td>
<td>6.28 (5.92–6.61)</td>
<td>0.08&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Insulin 120 (μU/ml)</td>
<td>182 (129–235)</td>
<td>77 (63–91)</td>
<td>&lt;0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.41 (3.83–4.99)</td>
<td>4.14 (3.81–4.31)</td>
<td>0.16&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.72 (1.57–1.87)</td>
<td>0.80 (0.73–0.87)</td>
<td>&lt;0.001&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>0.96 (0.93–0.99)</td>
<td>1.30 (1.27–1.33)</td>
<td>&lt;0.001&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>2.71 (2.42–3.02)</td>
<td>2.48 (2.31–2.65)</td>
<td>0.16&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Uric acid (μmol/l)</td>
<td>351 (314–388)</td>
<td>283 (267–299)</td>
<td>&lt;0.01&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.
<sup>a</sup>Mann–Whitney U test for independent non-parametric data.
<sup>b</sup>Student’s t-test for independent parametric data.
in some genetically predisposed individuals are elevated in relation to higher abdominal adiposity (1). However, more prospective studies will be necessary in order to clarify this relationship.

The absence of influence of age or Tanner pubertal stage in hs-CRP levels shows the utility of this parameter as a metabolic risk marker in early stages of life (8).

A limitation of our study is that with the multivariate model built we only partially explain the changes observed in hs-CRP. Therefore, it is necessary to carry out more studies that take into consideration other variables such as adiponectin, interleukin-6 and tumor necrosis factor-α, considered by other authors and which in this case have not been studied (13).

In short, hs-CRP seems to be an excellent marker in order to distinguish the presence of metabolic syndrome among obese children and adolescents and could be a useful tool for the early detection of cardiovascular risk factors among this population.

Disclosure

The work presented does not have any source of funding. There is no conflict of interest that would prejudice its impartiality.

References


www.eje-online.org

Figure 1 Linear regression analysis among hs-CRP and BMI, triglycerides, HDL-cholesterol and basal insulin.


Received 17 April 2008
Accepted 22 April 2008